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ABSTRACT 
Valsartan (VAL) is an antihypertensive drug marketed in an amorphous form. Amorphous materials can 
have different physicochemical properties depending on preparation method, thermal history etc., but the 
nature of such materials is difficult to study by diffraction techniques. This study characterizes two 
different amorphous forms of valsartan (AR and AM) using solid-state NMR (SSNMR) as a primary 
investigation tool, supported by solution-state NMR, FT-IR, TMDSC and dissolution tests. The two forms 
are found to be clearly distinct, with a significantly higher level of structural arrangement in the AR form, 
as observed in 
13
C, 
15
N and 
1
H SSNMR. 
13
C and 
15
N NMR indicates that the fully amorphous material 
(AM) contains an approximately equal ratio of cis–trans conformers about the amide bond, whereas AR 
form exists mainly as one conformer, with minor conformational “defects”. 1H ultra-fast MAS NMR 
shows significant differences in the hydrogen bonding involving the tetrazole and acid hydrogens 
between the two materials, while 
15
N NMR shows that both forms exist as an 1,2,3,4-tetrazole tautomer. 
NMR relaxation times show subtle differences in local and bulk molecular mobility, which can be 
connected with the glass transition, the stability of the glassy material and its response to ageing. 
Counter-intuitively the fully amorphous material is found to have a significantly lower dissolution rate 
than the apparently more ordered AR material. 
ABSTRACT GRAPHICS 
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valsartan, amorphous form, cis–trans amide conformers, solid-state NMR, molecular mobility, glass 
transition, dissolution  
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INTRODUCTION  
Valsartan (VAL, Figure 1A) is an antihypertensive drug belonging to the angiotensin II receptor 
antagonists class called sartans,1 which is marketed in an amorphous form. Such solids differ from 
crystalline materials in lacking long-range order, although some short-range order may be present.2, 3 
Amorphous active pharmaceutical ingredients (APIs) have been used in the development of 
pharmaceutical solid formulations due to factors such as increased solubility and dissolution rate 
compared to crystalline forms.4-6 However, amorphous APIs are usually less stable than their crystalline 
counterparts. The occurrence of polymorphism in crystalline pharmaceuticals and its impact on 
physicochemical properties is well documented,7-10 but it is also known that amorphous materials can 
have different physicochemical properties, depending on previous thermal history, time of storage and 
preparation method.11-15 Amorphous materials can exist in different kinetic states, and the term 
pseudopolyamorphism or relaxation polyamorphism has been used to describe this phenomenon.2 
Polyamorphism, the possible existence of two or more distinct amorphous forms of the same compound 
separated by a clear phase transition has been reported for inorganic compounds16-18 and discussed in the 
context of pharmaceuticals,2, 10, 12, 19 although, to our knowledge, there is no definitive example of 
polyamorphism in pharmaceutics. 
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Figure 1. (A) Chemical structure of valsartan (N-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine) with all carbons and 
nitrogens numbered. Numbering scheme used as in Refs.20, 21 The dihedral angle C-6–N-1–C-5–O-1, τ, that determines 
the amide cis (τ ≈180°) vs trans (τ ≈ 0°) conformation, as defined in Ref.21, is shown. (B) The structure of the 
independent molecule of valsartan in the asymmetric unit and hydrogen bonding adapted from Ref.20 The τ torsion 
angle is ~171°, corresponding to the cis isomer. Hydrogens are omitted for clarity. 
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Despite a wide variety of analytical techniques available, the structural characterization of subtle 
differences between different amorphous forms of active pharmaceutical ingredients remains challenging. 
It is also important to understand the nature of molecular mobility in amorphous APIs, because molecular 
relaxation may take place during storage. Solid-state NMR (SSNMR) has been widely used to study 
molecular dynamics in pharmaceutics.
22-25
 For example, Luthra et al. studied changes in molecular 
dynamics of model drug systems during annealing by Differential Scanning Calorimetry (DSC)
26
 and 
13
C 
NMR relaxation times.
27
 They observed that in most cases annealing leads to longer T1 and T1ρ NMR 
relaxation times, indicating a slowing of the local dynamics. Abdul-Fattah et al. observed that higher 
temperature annealing decreased molecular mobility as measured by isothermal calorimetry and improved 
chemical stability.
28
 
Various analytical methods have been used to characterize the solid state of valsartan. Tran et al. 
studied the influence of various types of solvents on the re-crystallisation behaviour of two sources of 
valsartan by DSC, powder X-ray diffractrometry (PXRD) and scanning electron microscopy,
29
 and found 
significant differences in morphology, structure and dissolution rate among the recrystallized samples. 
The lack of strong Bragg diffraction peaks in the PXRD results suggest, however, that most of the forms 
produced were essentially amorphous with different levels of local order rather than crystalline. The 
commercially available form (termed here the as-received, or AR, form) and the amorphous form 
obtained by quench-cooling (here called the AM form) were characterized by us using thermal methods 
and PXRD.
30
 The studies revealed significantly different glass transition temperatures for both materials 
and a higher degree of structural ordering in the marketed form. The crystal structure of a highly 
crystalline form of valsartan and its ethanol solvate have been recently published,
20
 characterized by 
various solid-state techniques and compared to the marketed amorphous form. 
Solid-state NMR is a powerful technique for the characterization of solid pharmaceuticals.
22, 31, 32
 
SSNMR has the advantage of providing localised chemical information on the crystalline or amorphous 
state, unlike bulk methods such as DSC or PXRD. SSNMR was successfully employed to characterize 
different polymorphic and amorphous forms of other sartans (candesartan, irbesartan and losartan).
33-35
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Bauer et al. reported that the closely related system irbesartan exists in two different crystal structures due 
to tautomerism in the tetrazole ring.
33
 
The focus of this study was to characterize two different amorphous forms of valsartan to provide 
insight into their amorphous structures and molecular mobility, employing solid-state NMR as a primary 
investigation tool supported by solution-state NMR, FT-IR, and TMDSC. Dissolution tests were also 
carried out to compare dissolution rates of the two forms. 
EXPERIMENTAL SECTION 
Materials 
Valsartan (form AR, as-received, pharmaceutical grade) was obtained from Polpharma, Starogard 
Gdański, Poland and used without further treatment. The non-crystalline nature of the material was 
confirmed by PXRD (see Figure S1 of the Supporting Information) and the lack of birefringence when 
analyzed by polarizing light microscopy. We have also analyzed materials from two other suppliers 
(Zydus Cadila, Ahmedabad, India and Wuhan Fortuna Chemical Co. Wuhan, China) and all samples were 
essentially identical by DSC and TMDSC as the sample (AR) used here. Its fully amorphous form (form 
AM) was prepared immediately prior to experimental measurements in DSC pan in the instrument, in the 
NMR rotor in the probe or in an oven, by heating sample to 130–140 °C, holding for 10–20 min then 
cooling with at least approximately 3 °C min
–1
 cooling rate to room temperature. The purity of both AR 
and AM materials was verified by solution 
1
H and 
13
C NMR. 
Attempts to obtain crystalline material by re-crystallization based on previous published reports 
or patents
20, 36-39
 were unsuccessful. 
Intrinsic and apparent dissolution testing 
The Intrinsic Dissolution Rate (IDR) of both amorphous samples was measured by the rotating disc 
method
40
 using the Wood apparatus in an Erweka DT60 dissolution testing station (ERWEKA GmbH, 
Germany). 150 mg of API was compressed at 1300 psi and held for 40 s in a die to form an 8 mm 
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diameter disc. Dissolution studies were performed in 900 mL of deionisedand deaerated water (pH = 6.9, 
conductivity < 0.1 µS cm
–1
) maintained at a temperature of 37 ±0.5 °C and disk rotation speed of 100 
rpm. Dissolution studies were carried out for 120 minutes and the concentration of API was determined 
on-line every 1 minute by a UV spectrophotometer at 250 nm (120 points). All measurements were 
performed in triplicates. IDR, the rate of mass transfer from solid to liquid state when conditions such as 
surface area, pH, ionic strength and stirring speed are kept constant, was determined using the following 
equation
41
: 
IDR =
𝐶
𝑡
𝑉
𝑆
 = 𝑘𝐶s  (1) 
where C is the drug concentration at time t, V is the volume of the test solution, S is the surface area of the 
disc, k is intrinsic dissolution rate constant, and Cs is the saturation solubility of the drug. The IDR was 
calculated from slope of each curve for a time period of 0–120 min. 
The apparent dissolution of both amorphous samples was measured by an on-line closed loop 
semi-automated flow through a cell dissolution system (SOTAX AG, Switzerland) using the Apparent 
Dissolution method defined in Chapter 2.9.43 of the Ph. Eur. 8.0.
42
 The dissolution system consisted of: 
SOTAX CE 7 unit, SOTAX CP 7-35 piston pump, reservoirs for the dissolution medium (SIMAX 1 L 
orange glass bottles placed on magnetic stirrers with integrated temperature control plate) and double-
beam UV-Vis spectrophotometer Nicolet Evolution 300 (Thermo Electron Corporation, USA). Each 
12 mm diameter cell was prepared by placing a 5-mm ruby bead in the apex of the cone to protect the 
inlet tube, and glass beads were added to the cone area to form a bead bed. Two sieves separated by a 
glass microfiber filter (GF/D Whatman with a retention capacity of 2.7 μm) and 50 mg of powder to be 
studied were respectively placed on the top of the layer of beads. The cell was closed with the prepared 
insert and the filter head consisting of one sieve and a glass microfiber filter (GF/F Whatman with a 
retention capacity of 0.7 μm). The closed-loop configuration used a 1000 mL of deaerated ultra-pure 
water (pH = 6.9, conductivity < 0.1 µS cm
–1
) per cell. Deaeration was performed using the SOTAX 
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Media Preparation Station. Reservoirs were placed in the line at RT-10 Power IKAMAG magnetic stirrers 
(IKA, Germany) allowing the medium to be stirred, heated and sampled. The medium was circulated with 
a constant flow rate of 8 mL min
–1
 (±2%) and maintained at 37.0 ±0.5 °C. After passing through the cell, 
the eluents were filtered and then transferred directly through the UV spectrometer. Measurements at 
250 nm were taken in flow-through cuvettes with 10 mm path length every 1 min up to 120 min. The 
WinSOTAX Plus Dissolution Software automatically read the baseline for each cell, recorded raw 
absorbance data, corrected data, and calculated concentration and % of dissolved drug. The measuring 
system consisted of seven chambers, allowing six powders to be tested simultaneously, with one chamber 
filled only with dissolving medium (blank sample). Each sample was tested in three chambers 
simultaneously (n = 3) and the final results were reported as an average, with the uncertainty represented 
by standard deviation (±SD). The drug dissolution and release profiles were plotted as the percentage of 
dissolved drug as a function of time. To quantify the in vitro dissolution kinetics, the first-order model:  
𝐹(𝑡) = 𝐹0[1 − exp(−𝑘D𝑡)] (2) 
(where F is the fraction of drug dissolved at time t and kD is the dissolution rate constant
43
) was fitted to 
the three individual dissolution profiles with linear least-squares curve-fitting technique using DDSolver 
software.
44
 
NMR measurements 
Solution-state NMR experiments were carried out on a Varian VNMRS-700 machine with 
1
H and 
13
C 
frequencies of 699.73 and 175.97 MHz respectively. Spectra of valsartan were measured in 0.5 mL of 
[D6]-DMSO. All measurements were performed at 25 °C. 
Carbon-13 solid-state NMR spectra were acquired using a Varian InfinityPlus spectrometer 
operating at a 
13
C frequency of 125.68 MHz. A magic-angle spinning (MAS) probe using 5 mm diameter 
zirconia rotors was employed. Typical operating conditions used cross-polarisation (CP) for excitation of 
the 
13
C magnetisation with a CP contact time of 2 ms, a recycle delay of 2 s, 512 to 2048 transients and 
spin rate of 6 or 10 kHz. Carbon chemical shifts were referenced to the signal for tetramethylsilane via a 
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replacement sample of solid adamantane (38.4 ppm for the high-frequency line). Variable-temperature 
experiments were performed from 38 °C to 110 °C, allowing samples to stabilize for 15–20 min before 
starting acquisition. Unless otherwise stated, temperatures in these experiments are quoted with a 
correction of +16 °C above the displayed temperature, which is the estimated increase in sample 
temperature for a 5 mm rotor spinning at 10 kHz, based on previous calibration experiments using lead 
nitrate.
45
 
Carbon-13 T1 relaxation times were measured with cross polarisation using the “Torchia” 
method,
46
 although without 
1
H decoupling during the relaxation period, using 21 recovery periods, τ, from 
0.01 to 80 s, acquiring 64 transients per point. T1 values were obtained by fitting the measured peak 
heights (after applying a Gaussian line broadening of 80 Hz) as function of τ to a simple mono-
exponential decay. Molecular motions on the kHz time scale were probed by measuring 
1
H via 
13
C spin-
lattice relaxation times in the rotating frame, T1ρ. Spin-locking pulse lengths were varied in 20 steps from 
1 to 20 ms, following a 90° radio frequency pulse (4.2 μs) and the peak heights as a function of pulse 
length fitted to a mono-exponential decay. The overlapped signal at 27.5 ppm showed multi-exponential 
character, and so was not fitted. The T1
C
 values for non-protonated carbons (C-5, C-10 and C-24 carbons) 
were too long to measure with any precision. 
Proton MAS spectra were recorded using a Varian InfinityPlus 500 spectrometer operating at a 
1
H frequency of 499.70 MHz. A Bruker MAS probe using 1.3 mm diameter zirconia rotor was employed. 
Spectra were typically acquired using a recycle delay of 10 s, 64 transients and spin rate of 67 kHz. 
Spectra were also recorded at 43 and 53 kHz spinning rate, where frictional heating is significantly lower, 
gave identical results apart from lower spectral resolution. Proton broadline NMR spectra and proton 
relaxation times (T1
H
 and T1ρ
H
) for static samples were measured at 299.82 MHz using a Varian UnityPlus 
spectrometer. T1
H
 was measured using saturation-recovery experiments. Spectra were measured over a 
temperatures range from 25 to 120 °C, allowing at least 15 min for stabilization before acquisition. All 
measurements were performed in duplicates for two different samples. Uncertainties listed are the 
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standard errors in the parameters as determined from non-linear regression analysis using SigmaPlot 12.0 
(Systat Software Inc.). 
Nitrogen-15 solid-state NMR spectra were recorded with CP and MAS using the Varian VNMRS 
and the Varian InfinityPlus spectrometers, operating at 
15
N frequencies of 40.53 and 50.65 MHz 
respectively, and probes taking 6 mm and 5 mm diameter rotors respectively. Typical operating 
conditions used a CP contact time of 5 or 10 ms, a recycle delay of 1.5 or 2 s, 40000 to 150000 
transients and spin rate of 6 or 10 kHz. Nitrogen chemical shifts were referenced using 
15
N-enriched 
glycine at –347.4 ppm relative to the signal of neat nitromethane. Variable-temperature experiments were 
performed at 38, 80 and 110 °C, allowing samples to stabilize for 15–20 min before starting acquisition. 
Unless otherwise stated, temperatures on the 5 mm probe and 10 kHz spinning rate are quoted with a 
correction of +16 °C as for the 
13
C SSNMR experiments. Inversion-recovery (IR) CP MAS experiments 
were recorded with inversion time of 1 ms as described in Ref.
47
 
The 
1
H–13C Heteronuclear Correlation (HETCOR) spectra were obtained at ambient temperature 
using the Varian VNMRS 400 spectrometer employing 4 or 6 mm rotors, with Frequency Switched Lee-
Goldburg CP, two-pulse phase modulation decoupling, contact times of 0.1 and 1.0 ms, 32 increments in 
the indirect dimension, 288 or 512 transients, recycle delays of 2 s and a spin rate of 10 kHz. A sample of 
glycine was employed for calibration. 
NMR data were processed using gsim
48
 and ACD/Spectrus Processor (Advanced Chemistry 
Development Inc.). Unless stated otherwise, Gaussian line broadening of 40 Hz and 60 Hz were applied 
to the 
13
C and 
15
N spectra respectively. A “resolution enhancement” corresponding to an 80 Hz Gaussian 
function was applied to the 
1
H MAS spectra. 
Gauge Including Projector Augmented Wave
49, 50
 calculations were carried out with the CASTEP 
v. 6.0 computer program
51
 for the crystalline valsartan given in Ref.
20 All calculations were performed 
using the PBE functional
52
 using on-the-fly generated ultrasoft pseudopotentials. Geometry optimisations 
for all atoms were carried out with the centre of mass fixed and a cut-off energy of 600 eV, with integrals 
taken over the Brillouin zone using a Monkhorst–Pack grid53 with 12 k-points and the unit cell parameters 
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fixed to the values determined by single crystal XRD. NMR calculations used the same cut-off energy 
and Brillouin zone integration. 
FT-IR measurements 
Fourier transform infra-red spectroscopy was carried out using an Alpha Bruker FT-IR spectrometer in 
KBr pellets. Spectra were recorded at room temperature from 4000 to 500 cm
–1
 collecting 64 scans with a 
resolution of 2 cm
–1
. 
TMDSC measurements 
Temperature-modulated DSC (TMDSC) curves were obtained using a DSC Q1000 TA Instrument Inc. 
(V9.9 Build 303) with an underlying heating rate of 3 °C min
–1
 and a temperature modulation with 
amplitude of 1.5 °C and period of 60 s (this is sometimes termed “standard TMDSC”) from 25 to 120 °C 
under a nitrogen gas flow of 50 mL min
–1
. The samples were then cooled at 25 °C min
–1
 to 20 °C without 
modulation and reheated to 120 °C with modulation in a second run. 
The enthalpy change after isothermal physical ageing was determined as a function of ageing 
time. Samples were first heated to 120 °C and held for several minutes to eliminate the effect of prior 
thermal history and then cooled at 25 °C min
–1
 below the glass transition temperature to the ageing 
temperature, Ta, which was 30, 40, 50 or 60 °C. The samples were maintained at Ta for specified 
times ranging from 0 to 16 hrs, and then cooled at 25 °C min
–1
 to 25 °C. A subsequent heating scan at 
3 °C min–1 by TMDSC to 120 °C provides the data for the aged samples.54, 55 The modulation parameters 
were the same as above. 
The equipment was calibrated with indium (m. p. = 156.65 °C, ΔHf = 28.45 J g
–1
), and at least 
two tests were run on each sample. Relaxation events are quoted as an onset temperature. Glass transition 
temperatures are quoted as midpoints. All values were determined using TA Universal Analysis 2000 
V4.5A software. Errors are quoted as one standard deviation. 
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RESULTS AND DISCUSSION 
Intrinsic dissolution rate (IDR) and apparent dissolution rate (ADR) 
The dissolution profile of an API can have a profound impact on both pharmacokinetic and 
pharmacodynamic parameters.
56
 Figure 2A shows intrinsic dissolution profiles for AR and AM valsartan 
in deionised water. AR valsartan showed significantly higher IDR value of 24.6 ±0.1 μg min–1 cm–2 
compared to 11.0 ±0.1 μg min–1 cm–2 for the AM sample (t-test at α = 0.05, p = 0.00003). Apparent 
dissolution tests of the powdered drugs in deionised water, Figure 2B, also show significant differences 
(t-test at α = 0.05, p = 0.00225) between the first-order dissolution rate constants, kD  (14.3 x 10
-4
 min
–1
 vs 
7.5 x 10
-4
 min
–1
 for AR and AM forms respectively). The higher free energy of amorphous materials is 
generally associated with increased solubility and dissolution rates.
4-6
 It is, therefore, surprising to find 
that the fully amorphous material (AM form) has the lower dissolution rate. 
13 
 
 
Figure 2. (A) Intrinsic and (B) apparent dissolution profiles of valsartan in different solid state forms in deionised water. 
Carbon-13 SSNMR 
Figure 3 shows 
13
C CP MAS NMR spectra of the two valsartan forms. Both spectra are relatively broad, 
reflecting the amorphous nature of the materials as reported elsewhere (see Figure S1 of Supporting 
Information).
30
 The resonances were assigned based on 
13
C solution-state NMR and by computational 
prediction of chemical shifts based on the crystal structure of Ref.
20
, although assignment is limited by 
peak overlap and the broadness of the resonances. Table I lists the chemical shifts for two solid-states of 
valsartan and compares them to corresponding solution-state and calculated values. 
14 
 
 
Figure 3. 13C CP MAS NMR spectra of as-received valsartan (AR form) at (A) 38 °C, (B) above the glass transition temperature 
at 110 °C and (C) fully amorphous valsartan (AM form) at 38 °C. Spectra recorded at 10 kHz spinning rate, asterisks 
denote spinning sidebands. Insets show 40–70 ppm region of spectra recorded at 6 kHz spinning rate, which are less 
affected by spinning sidebands.  
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Table I Solution-, solid-state and calculated 13C chemical shifts for valsartan at 25 °C (in [D6]-DMSO) and 38 °C (solid state). 
Carbon 
No 
Solution-state NMR δC / ppm Solid-state NMR δC / ppm 
Calculated 
δC(calc) / ppm
a
 
Major conformer 
(trans) 
Minor conformer 
(cis) 
AR VAL AM VAL 
Crystalline 
VAL (cis) 
1 14.16 14.25 14.1 14.3 11.8 
8 18.25 18.93 
19.8 
22.6 
27.6 
19.8 
22.6 
28.0 
22.3 
2 22.12 22.27 24.7 
9 20.59 19.84 25.2 
3 27.26 27.45 27.9 
7 28.00 28.04 29.8 
4 32.90 32.94 34.1 33.8 34.3 
11 49.15 45.90 46.2 48.3 51.2 
6 63.39 66.18 65.8 62.3, 67.3 73.1 
23 123.50
b
 123.50
b
 121.3 
123 – 139 
with maxima 
at 130.1 
138.0 
129.7 
19 130.98 131.05 
123 – 139 with 
maxima at 
129.7 
131.8 
138.5 
135.5 
21 128.14 128.01 136.2 
16 129.24 128.73 136.2 
14 129.24 128.73 136.9 
13 126.72 127.37 137.4 
17 126.72 127.37 138.5 
20 130.98 131.05 139.0 
22 131.51 131.51 142.7 
12 138.22 137.55 143.9 
15 138.22 138.67 145.2 
18 141.65 141.78 140.8 141.9 150.4 
24 155.00
b
 155.00
b
 155.1 155.1 166.1 
10 172.34 172.07 171.7 171.3 180.6 
5 173.91 173.88 176.8 177.3 181.8 
a δC(calc) = σref – σcalc  where σref = 176.1 ppm cf. Figure S2A of  Supporting Information. 
b Not observed. Data taken from Ref.57, acquired in 1:1 [D6]-DMSO/D2O solution 
The main difference between AR and AM spectra is for carbons directly bonded to the amide 
nitrogen (N-1) i.e. C-11 and C-6. In the fully amorphous material, the C-11 signal is broadened and at 
higher chemical shift (ΔδC = +2.1 ppm). The C-6 resonance at 65.8 ppm in the AR spectrum is split into 
two broad signals with maxima at 62.3 and 67.3 ppm in the AM form spectrum (clearer in the insets 
acquired at 6 kHz MAS rate in Figure 3C). The 
1
H–13C HETCOR spectrum also clearly showed a pair of 
cross-peaks from C-6 in the AM form (Figure S3, Supporting Information). Valsartan in solution exists in 
two conformations (cis–trans) due to restricted rotation around the C(O)–N amide bond,21, 57 cf. Figure 1. 
Significant differences can be observed for C-11 and C-6 solution-state chemical shifts for cis and trans 
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conformers (for C-11, δC
cis
 = 45.90, δC
trans
 = 49.15 ppm and for C-6, δC
cis
 = 66.18, δC
trans
 = 63.39 ppm), 
where the cis vs trans assignment was made on the basis of NOESY experiments. These indicated that 
trans conformation is favoured in DMSO solution, while the cis conformation is exclusively occupied in 
the only known crystal structure.
20
 The splitting of the C-6 signal and broadening of the C-11 signal in 
solid-state NMR experiments suggests that AM form of valsartan contains an approximately equal ratio of 
cis and trans conformers. Care is required when comparing chemical shifts between solid and solution 
states. However, the trend line for computed chemical shifts from the known solid-state form (cis 
conformation), Figure S2 of Supporting Information, is a better fit for the 
13
C solution-state shifts of the 
cis rather than trans conformation. Taken together with the excellent agreement of the AR form shifts 
with the cis solution-state shifts, this strongly suggests that the AR form involves the cis isomer. In 
contrast to the aliphatic region below 40 ppm, the signals at higher frequency, from the phenyl rings, the 
carbon in the tetrazole ring (C-24), the amide and acid carbons (C-5, C-10), all broaden significantly in 
the AM spectrum. 
Heating both materials above the glass transition results in indistinguishable 
13
C NMR spectra, 
Figure 3B (full results shown in Figures S4 and S5 of the Supporting Information), showing that both 
starting materials have “relaxed” to the same form. The aliphatic peak linewidths (C-1–C-4 and C-7–C-9) 
are noticeably sharper at 110 °C, which corresponds to increased molecular mobility. In contrast there is 
little narrowing of the aromatic region, implying that the mobility of the alkyl regions is local rather than 
affecting the molecules as a whole. Equalisation of the cis vs trans distribution has occurred for the AR 
form during its glass transition. Similar behaviour for an API, captopril, containing amide bond but in an 
initially crystalline form, was observed during melting of an initially crystalline material by Wang et. al. 
using VT FT-IR microscopy.
58
 Similarly amide cis–trans interconversion in the solid state was postulated 
as the origin of polymorphism in fosinopril sodium using SSNMR and FT-IR.
59
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1
H solid-state NMR 
Wideline (static) 
1
H NMR spectra of the two forms as a function of temperature are very similar, and 
show the expected narrowing of NMR spectrum above the glass transition as a result of increased 
mobility, cf. Figure S6 of the Supporting Information. 
1
H spectra acquired under ultra-fast magic-angle 
spinning to reduce the line-broadening associated with the strong dipolar interactions between 
1
H spins 
are more informative. As shown in Figure 4, five resonances are clearly distinguished in the spectrum of 
as-received valsartan, corresponding to alkyls (≈0.9 ppm), alkyls bonded with N-1 (≈5.6 ppm), aromatic 
(≈7.1 ppm), acidic (≈14.2 ppm) and tetrazole (≈16.4 ppm) protons. The C-6 and C-11 signals are not 
resolved for the amorphous form. The assignment of the high frequency signals was based on the 
CASTEP-predicted 
1
H shifts using the crystal structure of valsartan given by Wang et al. (Figure 1B);20 
the calculated shielding is +2.4 ppm higher for the acidic proton compared to the tetrazole, which is a 
good match for the experiment shift difference of –2.2 ppm (accounting for the opposite directions of 
shielding and chemical shift scales). In this structure, valsartan molecules are connected via two hydrogen 
bonds, both associated with the tetrazole ring: one between the carboxylic acid group (C-10) and N-2, and 
the other one between the carbonyl group (C-5) and N-5. The 
1
H MAS experiments are consistent with 
the tetrazole (N(5)H) and acidic (C(10)OOH) protons being involved in similar hydrogen bonding 
arrangements in the crystalline and AR forms. In contrast, the 
1
H spectrum of the fully amorphous form 
shows a single very broad feature in this region implying a much wider distribution of hydrogen bonding 
environments in the AM form. 
18 
 
 
Figure 4. 1H MAS NMR spectra of (A) as-received (AR form) and (B) fully amorphous (AM form) valsartan recorded at a MAS 
rate of 67 kHz. 
Nitrogen-15 SSNMR 
Solid-state 
15
N CP MAS NMR has been successfully employed to examine polymorphism of a closely 
related system, irbesartan.
33
 Like irbesartan, valsartan can potentially exist in two tautomeric forms of the 
tetrazole ring i.e. as 1,2,3,4-tetrazole or 1,2,3,5-tetrazole as presented in Figure 5A. Figure 5B–E shows 
15
N CP MAS NMR spectra of both valsartan forms. The spectrum of the as-received material, Figure 5B, 
has the expected five strong signals (tetrazole + amide nitrogen), but also weak signals at about –52, –160 
and –255 ppm. The spectrum of the AM form shows broader signals in the same positions, but these 
smaller signals are significantly stronger. Assignments are made by comparison with literature 
15
N data 
for tetrazole-containing systems, computational prediction of chemical shifts for crystalline valsartan, and 
experimental determination of the protonation site. 
15
N dipolar dephasing experiments were unsuccessful, 
presumably because the 
15
N,
1
H dipolar couplings are too strongly affected by the magic-angle spinning 
required for site resolution,
60
 but the inversion recovery CP MAS experiment,
47
 Figure 5E, clearly 
identified the signal at –149.4 ppm as the protonated nitrogen. As seen in Table II and Figure S2B of the 
Supporting Information, the assignment is excellent agreement with the computational prediction of 
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chemical shifts for crystalline valsartan and is in much better agreement with the 1,2,3,4-tetrazole 
tautomer of irbesartan (form A) rather than the 1,2,3,5-tetrazole (form B). Hence we can conclude that 
both AR and AM forms of valsartan exist as a 1,2,3,4-tetrazole tautomer. The significantly better 
agreement of the computed shieldings of the crystalline form (cis conformer) with the strong peaks of the 
AR form again suggests that the strong peaks correspond to the cis conformer. The additional weak 
signals in the AR form, which are stronger in the AM form, are likely to correspond to the trans 
conformer. The crowded nature of the spectrum means that the weak peaks from the minor conformer 
cannot be confidently identified in the 
13
C spectrum of the AR form, although the spectrum is clearly not 
inconsistent with their presence.  
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Figure 5. (A) Possible tautomeric forms of valsartan: 1,2,3,4- and 1,2,3,5- forms. 15N CP MAS NMR spectra of AR VAL (B) at 
6 kHz spinning rate (151 000 repetitions in total) (C) at 10 kHz spinning rate (30 000 repetitions in total), (D) AM VAL 
at 10 kHz spinning rate (40 000 repetitions) and (E) 15N IR CP MAS NMR spectrum of AR VAL at 10 kHz spinning 
rate (331 000 repetitions in total). Arrows () indicate signals from isomeric impurity in the AR form. (B) was acquired 
at 40.53 MHz and other spectra at 50.65 Mz. All spectra recorded at room temperature. Asterisks (*) denote spinning 
sidebands. Note N-(I–IV) in diagram A correspond to N-(5–2) in figure B, respectively. 
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Table II Nitrogen-15 chemical shifts for valsartan and other related tetrazole systems. 
Compound 
δN / ppm 
Ref. 
N-Ia N-IIa N-IIIa N-IVa N amide 
Major conformer in AR valsartanb 
(1,2,3,4-tetrazole) 
–149.4, 
(N-5) 
–13.2 
(N-4)  
10.3 
(N-3)  
–71.2 
(N-2) 
–247.3 
(N-1) 
this work 
Minor conformer in AR valsartanb 
(1,2,3,4-tetrazole) 
–160.3 
(N-5) 
–c –c 
–51.7 
(N-2) 
–254.9 
(N-1) 
this work 
Minor/major conformers in AM 
valsartanb (1,2,3,4-tetrazole) 
–152.5 
(N-5) 
–15.2 
(N-4) 
11.5 
(N-3)  
–53.6, 
–67.8 
(N-2) 
–253.3 
(N-1) 
this work 
Cis crystalline valsartan (calculated)b,d 
(1,2,3,4-tetrazole) 
–149.0 
(N-5) 
–18.4 
(N-4) 
13.8 
(N-3) 
–68.1 
(N-2) 
–244.1 
(N-1) 
this work 
Irbesartan form A (1,2,3,4-tetrazole) –143.4 –13.6 13.0 –54.2 –216.4 this work 
5-phenyltetrazole (1,2,3,4-tetrazole) –153.2 –16.9 5.1 –78.0 – 33 
Irbesartan form Be (1,2,3,5-tetrazole) 
–79.3 
(N-24) 
–88.7 
(N-25) 
–3.2 
(N-26) 
–50.7 
(N-27) 
–219.0f 33 
aNitrogen atom labelling is the 1,2,3,4-tetrazole convention as in Figure 5A. 
bLabels in parentheses are those used in this work and Ref.20 
cSignals not resolved. 
dδiso = σref  – σiso, where σref = –164.9 ppm (Figure S2B, Supporting Information). 
eLabels in parentheses are those used in Ref.33 
fValues originally reported with respect to nitrate resonance of solid external ammonium nitrate but here reported relative to nitromethane for 
consistency. 
 
Fourier transform infra-red spectroscopy (FT-IR) 
FT-IR measurements revealed only subtle differences between the two forms, cf. Figure S7 of the 
Supporting Information. AR valsartan shows absorption bands at 1732.1 cm
–1 and 1603.8 cm–1, assigned 
to carboxyl carbonyl (C-10) and amide carbonyl (C-5) stretching vibrations respectively, that are 
potentially sensitive to changes in hydrogen bonds. There was, however, no change in the AM form in the 
carboxyl carbonyl band (1732.1 cm
–1
), while the C-5 carbonyl peak shifted towards higher wavenumber 
(1605.8 cm
–1
). This is consistent with the differences in the forms relating to cis–trans conformational 
changes, although changes in the intermolecular hydrogen bonds between C(5)O and the tetrazole N(5)H 
group could also be a factor. As well as minor changes in the fingerprint region (inset of Figure S7), there 
is some attenuation of the broad peak centred about 3436 cm
–1
 (N(5)H and/or OH) which is likely to 
reflect changes in hydrogen bonding. 
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Molecular mobility from NMR relaxation times 
Variable-temperature, wideline (static) 
1
H spin-lattice relaxation time, T1
H
, experiments provide 
information on molecular mobility of both forms. T1
H
 is sensitive to motional processes of the order of the 
1
H NMR frequency,
25
 here 300 MHz, and is typically sensitive to high-frequency local motions. The T1
H
 
measurements show a monotonic increase in the T1 values with increasing temperature for both forms 
(Figure 6A), consistent with frequency of local motions increasing into the GHz range above ambient 
temperature. This increase is smooth through Tg, suggesting that the local motions are not significantly 
affected by the glass transition.
23, 61
 The values of T1
H
 are measurably different for the two forms at room 
temperature, but converge, as might be expected, as the glass transition is approached. 
 
Figure 6. Static proton (A) T1 and (B) T1ρ
H data for AR and AM valsartan forms. 
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Wideline measurements of T1
H
 provide an overview of high-frequency local motions which can 
be refined by measurements of 
13
C T1 relaxation times (at the expense of greatly increased experimental 
time), since these provide information on site-specific dynamics. The detailed values are given in Table 
SI of the Supporting Information and the results for characteristic carbons are shown in Figure 7. The 
relaxation behaviour of the aliphatic carbons of the butyl chain (C-1–C-3) and the isobutyl group, Figure 
7A–C, is very similar and essentially identical between forms. The temperature dependence of the 
dynamics driving the relaxation can be fitted by plotting the relaxation times as a function of the inverse 
of the temperature. This dependence can be interpreted, in terms of empirical activation barriers of the 
order of 8–12 kJ mol–1 (Figure S8, Supporting Information). Note how the major changes in bulk 
molecular mobility associated with the glass transition are not apparent from these relaxation times. In 
contrast, the aromatic carbons have relatively long relaxation times at ambient temperature which drop 
significantly at the glass transition, Figure 7E. This change is smooth for the truly amorphous material, 
but there is some evidence of a more step-like behaviour for the AR material. This suggests that the glass 
transition is associated with an “unlocking” of the aromatic rings. The relaxation time of C-4, Figure 7D, 
behaves somewhat differently to that of the other aliphatic carbons, which is consistent with amide group 
having different motional character to the alkyl chain and isobutyl group. 
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Figure 7. 13C T1 relaxation time constants of AR and AM valsartan forms as a function of temperature for (A–D) aliphatic and 
(E) aromatic carbons. 
The 
1
H T1ρ relaxation time is sensitive to motion on the order of the RF nutation rates,
25
 here 
125 kHz. Such slower processes are often associated with bulk mobility rather than the local 
high-frequency motions probed by spin-lattice relaxation times. The T1ρ
H
 as a function of temperature 
were obtained for the two forms of valsartan from wideline measurements, Figure 6B. The T1ρ
H
 values for 
the AR material below the glass transition are higher than for totally amorphous valsartan, but converge 
above Tg. These differences are much smaller than those typically observed between amorphous and truly 
crystalline materials.
24
 Experiments to measure site-specific 
1
H T1ρ values by transferring the partially 
relaxed 
1
H magnetisation to 
13
C via cross-polarisation prior to measurement were relatively 
uninformative, showing uniform behaviour across sites, cf. Figure S9 and Table SII of Supporting 
Information, although again a more step-like character to the temperature dependence was observed for 
the AR material. Spin-diffusion between 
1
H will tend to equalise T1ρ
H
 values, which may, in any case, be 
probing overall bulk mobility rather than site-specific motions. 
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The effect of annealing on the AM form 
During physical ageing amorphous materials lose excess enthalpy as they evolve towards more stable 
arrangements. This enthalpy loss is recovered by the system during the heating DSC step and is measured 
as an integral of enthalpy recovery peak, which overlaps with a change of heat capacity at glass transition 
on standard DSC. Such enthalpy relaxation reflects the molecular mobility in the glassy state.
62
 The 
impact of annealing at different temperatures below the glass transition was investigated by temperature-
modulated DSC. By imposing a time-dependent modulation on the temperature ramp, TMDSC 
decomposes the overall heat flow in a reversing (thermodynamic) and non-reversing (kinetic) heat-flow 
or heat capacity signal.
54
 Figure 8 shows the TMDSC traces for AM valsartan annealed at 50 °C for 
different periods. The enthalpy recovery peaks on the non-reversing curve, Figure 8C, increase and shift 
to higher temperatures as ageing time increases. Only the glass transition is observed on the reversing 
curve. This moves to higher temperature as ageing time increases. For example, Tg changes from 76.7 to 
77.3 °C, the onset of enthalpy relaxation peak from 67.4 to 70.4 °C and ΔH from 2.8 to 7.4 J g–1 after 16 h 
of annealing at 50 °C. For comparison, the glass transition of AR valsartan sample is 94.4 °C, and the 
onset of the enthalpy relaxation peak is 91.6 °C with ΔH = 15.8 J g–1. These results are consistent with the 
sample moving towards a more stable conformation during ageing, possibly towards conformational 
distribution of the AR form. The effect of annealing can still be clearly observed for samples annealed at 
40 °C, but is relatively low for samples annealed at 30 °C, Figure 9. It should be noted that the observed 
glass transition temperature is a function of the experimental cooling rate and thermal history of glassy 
materials,
62
 and so the values reported for valsartan determined by standard DSC and TMDSC do vary; 
the key information is contained in the relative changes of Tg. None of the measured TMDSC curves 
showed exothermic and/or endothermic behaviour due to crystallisation and melting, confirming the 
stability of amorphous valsartan. 
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Figure 8. (A) Change of total, (B) reversing and (C) non-reversing heat capacity of AM valsartan annealed at 50 °C for different 
lengths of time from 0 to 16 hours. 
 
Figure 9. Enthalpy lost with time on structural relaxation of AM valsartan annealed at 30, 40 and 60 °C. The value of enthalpy 
relaxation at Ta = 0 h was subtracted from values of enthalpies of annealed samples to exclude effect of thermal 
history during cooling/heating scan. The relative standard deviations of enthalpy measurements were less than 10%. 
Lines drawn between points are guides for the eye. 
27 
 
As summarised in Table III, wideline T1
H
 and T1ρ
H
 relaxation times were measured for an AM 
sample annealed at 60 °C, i.e. 24 °C below Tg (as determined by standard DSC). Although the changes in 
relaxation times are relatively small compared to the experimental uncertainties, both T1
H
 and T1ρ
H
 values 
tend towards those of the AR material with increased annealing time. This is consistent with the mobility 
behaviour of the amorphous material evolving towards that of the AR material as a result of annealing. 
T1
C
 relaxation times were measured for the annealed material, but the poorer signal-to-noise ratio in these 
experiments meant that any variations were too small to be observed. Similarly, changes in the 
13
C 
spectrum on annealing were too small to be observed. Note that no significant changes were observed by 
TMDSC after ageing of the AR sample at 60 °C for up to 16 hours.  
Table III T1
H and T1ρ
H relaxation times for fully amorphous valsartan form (AM) as a function of annealing time. Relaxation 
times for AR form shown for comparison. Uncertainties listed are the standard errors in the parameters as determined 
from nonlinear regression analysis. 
Annealing time / h 
T1
H
 / s T1ρ
H
 / ms 
AR AM AR AM 
0 0.97 ±0.004 1.53 ±0.007 14.86 ±0.21 11.64 ±0.11 
1 
N/A 
1.28 ±0.027 
N/A 
11.69 ±0.16 
3 1.33 ±0.009 11.48 ±0.13 
19 1.25 ±0.014 12.26 ±0.18 
 
CONCLUSIONS 
The molecular structures and mobility of two solid-state forms of valsartan were investigated by 
solid-state NMR supported by solution-state NMR, FT-IR, TMDSC and dissolution testing. The two 
amorphous forms are found to be clearly distinct, with a significantly higher level of structural 
arrangement in the AR form, as observed in 
13
C and 
15
N NMR. Significant differences are noticed in the 
resonances from carbons directly bonded to amide nitrogen (N-1), which together with the 
15
N NMR, 
suggests that the fully amorphous material contains an approximate equal ratio of cis–trans conformers, 
whereas AR form contains mainly one conformer, most likely cis (as in the crystalline state), with some 
small fraction of the other conformer. FT-IR experiments showed subtle differences which are consistent 
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with these observations. Further differences between both forms were observed by 
1
H ultra-fast MAS 
NMR. The signals from protons bonded to C-6 and C-11 are broadened in the AM material due to 
amorphisation and changes in the cis–trans distribution, while changes in the high-frequency signals are 
consistent with significant differences in the hydrogen bonding involving the tetrazole and acid 
hydrogens. Nitrogen-15 NMR experiments confirmed that both forms exist as the 1,2,3,4-tetrazole 
tautomer. NMR relaxation times show subtle differences in local and bulk molecular mobility between 
both forms, which can be connected with the glass transition, the stability of the glassy material and its 
response to ageing. 
Both intrinsic and apparent dissolution profiles show significant differences in dissolution 
kinetics for examined amorphous solid-states of valsartan. As amorphous materials have higher free 
energy, they usually have a greater solubility and dissolution rate than corresponding crystalline forms. 
Surprisingly, the less ordered, fully amorphous material (AM) has significantly lower dissolution rate 
than the apparently more ordered AR material. The results demonstrate that the method of preparation of 
amorphous valsartan can have a significant impact on its dissolution behaviour. These differences in 
dissolution rate are probably associated with the differences in hydrogen-bonding arrangements observed 
via 
1
H NMR. 
Careful characterisation of amorphous APIs is crucial, due to their generally low chemical and 
physical stability. Approved by US Food and Drug Administration in 1996, valsartan has so far been 
marketed in an amorphous form; a highly crystalline form was only obtained and patented relatively very 
recently. Our studies help to understand both the difficulty in obtaining crystalline forms of valsartan and 
the existence and stability of different amorphous forms. The flexibility of the alkyl chain and the high 
barrier to conformational exchange about the amide bond are impediments to forming an ordered crystal 
lattice, with the difficulty of conformational exchange in the solid state allowing “defects” to be easily 
trapped, despite the enthalpic benefits of denser packing in the AR / annealed materials. This would both 
explain the stable nature of the truly amorphous AM form, as well as the existence of more ordered, but 
still non-crystalline materials formed when solutions of valsartan are “crystallised” from solution.29 
29 
 
Solid-state NMR, in conjunction with complementary methods, such as TMDSC, allows the molecular 
origins of the disorder in these materials to be probed. This in turn facilitates the design of future APIs, 
either to deliberately stabilise amorphous materials, or to avoid the risks of poorly crystalline forms. 
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